Trials / Recruiting
RecruitingNCT04644016
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Conditions
- AML
- ALL
- MDS
- MPD Withou Myelofibrosis
- NHL or HL
- Inherited Metabolic Disorders
- Hemoglobinopathies
- Bone Marrow Failure
- HLH
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clofarabine | Clofarabine |
| DRUG | Fludarabine | Fludarabine |
| DRUG | Busulfan | Busulfan per PK |
| DRUG | Cyclosporine-A | GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3. |
| DRUG | Mycophenolate Mofetil | GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3. |
| BIOLOGICAL | Cord Blood Graft | The CB graft will be infused on day 0 per standard practice |
Timeline
- Start date
- 2020-11-20
- Primary completion
- 2026-12-20
- Completion
- 2026-12-20
- First posted
- 2020-11-25
- Last updated
- 2026-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04644016. Inclusion in this directory is not an endorsement.